A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus.

Trial Profile

A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2012

At a glance

  • Drugs Orlistat; Peginterferon alfa-2a; Ribavirin
  • Indications Fatty liver; Hepatitis C; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2011 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 16 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Planned number of patients changed from 280 to 30 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top